| __timestamp | Arrowhead Pharmaceuticals, Inc. | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 23138050 | 21226345 |
| Thursday, January 1, 2015 | 57410147 | 87718074 |
| Friday, January 1, 2016 | 41454452 | 93831530 |
| Sunday, January 1, 2017 | 31690298 | 79419009 |
| Monday, January 1, 2018 | 52968505 | 132166913 |
| Tuesday, January 1, 2019 | 81048686 | 89124838 |
| Wednesday, January 1, 2020 | 128874979 | 65782137 |
| Friday, January 1, 2021 | 206342000 | 88845513 |
| Saturday, January 1, 2022 | 297307000 | 134715000 |
| Sunday, January 1, 2023 | 353188000 | 180142000 |
| Monday, January 1, 2024 | 505870000 |
Data in motion
In the ever-evolving landscape of biopharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Intra-Cellular Therapies, Inc. and Arrowhead Pharmaceuticals, Inc. have been at the forefront of this transformative journey. From 2014 to 2023, Arrowhead Pharmaceuticals has seen a staggering 1,400% increase in R&D expenses, reflecting its commitment to pioneering new therapies. Intra-Cellular Therapies, while slightly more conservative, has also doubled its R&D investment, underscoring its dedication to advancing mental health treatments.
Arrowhead's R&D spending peaked in 2023, marking a significant milestone in its strategic growth. In contrast, Intra-Cellular Therapies' R&D expenses reached their zenith in 2023, highlighting a robust pipeline. However, data for 2024 is incomplete, suggesting ongoing developments. This dynamic trend underscores the relentless pursuit of innovation in the biopharmaceutical sector, promising groundbreaking therapies for the future.
Sanofi or Intra-Cellular Therapies, Inc.: Who Invests More in Innovation?
Teva Pharmaceutical Industries Limited vs Arrowhead Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Research and Development Investment: Incyte Corporation vs Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. vs Insmed Incorporated: Strategic Focus on R&D Spending
R&D Insights: How Intra-Cellular Therapies, Inc. and Alpine Immune Sciences, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Intra-Cellular Therapies, Inc. and CymaBay Therapeutics, Inc.
Comparing Innovation Spending: Intra-Cellular Therapies, Inc. and HUTCHMED (China) Limited
Summit Therapeutics Inc. vs Arrowhead Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for Exelixis, Inc. and Arrowhead Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Pharming Group N.V. vs Arrowhead Pharmaceuticals, Inc.
Research and Development Investment: Axsome Therapeutics, Inc. vs Arrowhead Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Arrowhead Pharmaceuticals, Inc. and MannKind Corporation